TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28533151

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) with salvage radiation therapy (SRT)
Number of subjects: 4200

Group type: EXPERIMENTAL
Intervention: ADT use predictors: presurgery PSA >20 ng/ml (AOR = 1.34, P = 0.002; 36.7% vs. 29.6%), positive margins (AOR = 1.29, P = 0.001; 34.9% vs. 27.8%), Gleason scores (Gleason 3+4 AOR = 1.53; 21.3%, 4+3 AOR = 2.40; 32.0%, 8 to 10 AOR = 4.49; 49.2% vs. 2 to 6; P≤0.005 for all; 13.2%), pathologic T stages (T3a AOR = 1.46; 30.9%, T3b AOR = 2.50; 47.6%, T4 AOR = 4.14; 60.9% vs. T2; P<0.001 for all; 19.1%).
Number of subjects: 4200

Group type: EXPERIMENTAL
Intervention: Starting SRT 12 to 23.9 months after RP
Number of subjects: 4200

Group type: EXPERIMENTAL
Intervention: Starting SRT ≥24 months after RP
Number of subjects: 4200
Study: 25936452

Group type: EXPERIMENTAL
Intervention: EUS‐FNA with a stylet (S+)
Number of subjects: 107

Group type: COMPARATOR
Intervention: EUS‐FNA without a stylet (S‐)
Number of subjects: 107
Study: 24130354

Group type: EXPERIMENTAL
Intervention: 1 to 2 portions of fruits and vegetables (F&Vs) per day
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: 4 portions of fruits and vegetables (F&Vs) per day
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: 7 portions of fruits and vegetables (F&Vs) per day
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: All groups (1-2, 4, 7 portions of F&Vs)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control (washout diet of 1-2 portions of F&Vs per day)
Number of subjects: 89
Study: 21273210

Group type: EXPERIMENTAL
Intervention: Unweighted summed score
Number of subjects: 1101

Group type: EXPERIMENTAL
Intervention: Weighted summed score
Number of subjects: 1101
Study: 18937325

Group type: EXPERIMENTAL
Intervention: DTP vaccine (three doses administered)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no vaccination)
Number of subjects: 56
Study: 17707594

Group type: EXPERIMENTAL
Intervention: Brief Motivational Interview (BMI)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Computer-delivered intervention (CDI)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Booster condition
Number of subjects: 225
Study: 15483745

Group type: EXPERIMENTAL
Intervention: Patients with coronary artery disease
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Patients and Control subjects
Number of subjects: 250
Study: 11510750

Group type: EXPERIMENTAL
Intervention: Cilnidipine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Benazepril
Number of subjects: 20
Study: 10193254

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at 1 ppm
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at 10 ppm
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at 20 ppm
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 12
Study: 7921336

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo consumption
Number of subjects: 0
Study: 3396485

Group type: COMPARATOR
Intervention: Short course prophylaxis (2g cefotaxime IV at anaesthesia)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Long course prophylaxis (2g cefotaxime at anaesthesia plus 7 doses of 1g 12‐hourly)
Number of subjects: 293

Group type: COMPARATOR
Intervention: Both treatments (short and long course)
Number of subjects: 293
Study: 31831886

Group type: EXPERIMENTAL
Intervention: Leptin genetic risk score (GRS)
Number of subjects: 3860

Group type: EXPERIMENTAL
Intervention: Leptin genetic risk score (GRS) among current smokers
Number of subjects: 3860

Group type: EXPERIMENTAL
Intervention: Leptin genetic risk score (GRS) and smoking interaction
Number of subjects: 3860
Study: 29119704

Group type: EXPERIMENTAL
Intervention: RP5063 (10 mg fasting, 15 mg fed/fasting)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RP5063 (10, 20, 50, and 100 mg fed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RP5063 (single-dose study)
Number of subjects: 0
Study: 27225353

Group type: EXPERIMENTAL
Intervention: Moderate-intensity physical activity (PA)
Number of subjects: 1635

Group type: COMPARATOR
Intervention: Health education (HE)
Number of subjects: 1635
Study: 25687353

Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg every 2 weeks
Number of subjects: 720

Group type: COMPARATOR
Intervention: Ezetimibe 10 mg daily
Number of subjects: 720
Study: 23305463

Group type: EXPERIMENTAL
Intervention: Internet intervention 'Mastery over Dementia', consisting of an 8-session internet course with a booster session over a maximum period of 6 months, guided by a psychologist.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Minimal intervention (comparison condition).
Number of subjects: 0
Study: 20642207

Group type: EXPERIMENTAL
Intervention: FAHF‐2 (2.2 g, 3 times a day for 7 days)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: FAHF‐2 (3.3 g, 3 times a day for 7 days)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: FAHF‐2 (6.6 g, 3 times a day for 7 days)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (3 times a day for 7 days)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: In vitro studies with FAHF‐2
Number of subjects: 19
Study: 18622266

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CRHR1 SNPs
Number of subjects: 0
Study: 16306470

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 12682474

Group type: EXPERIMENTAL
Intervention: Stress doses of hydrocortisone (100 mg before induction of anesthesia, then 10 mg/hr for 24 hrs, 5 mg/hr for 24 hrs, 3 x 20 mg/day, and 3 x 10 mg/day)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Stress doses of hydrocortisone
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 91
Study: 10869915

Group type: EXPERIMENTAL
Intervention: Sevoflurane (8% in 50% nitrous oxide and oxygen)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Halothane (4% in 50% nitrous oxide and oxygen)
Number of subjects: 78
Study: 9184782

Group type: EXPERIMENTAL
Intervention: Folinic acid (15 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 8197889

Group type: EXPERIMENTAL
Intervention: Scheduled smoking procedure
Number of subjects: 34

Group type: COMPARATOR
Intervention: Minimal contact self-help treatment control
Number of subjects: 34
Study: 3581712

Group type: EXPERIMENTAL
Intervention: 3 weeks' anticoagulation with heparin and warfarin
Number of subjects: 100

Group type: COMPARATOR
Intervention: 6 weeks' anticoagulation with heparin and warfarin
Number of subjects: 100
Study: 29446041

Group type: EXPERIMENTAL
Intervention: Magnifying endoscopy with narrow band imaging (ME‐NBI)
Number of subjects: 24
Study: 27187773

Group type: EXPERIMENTAL
Intervention: Advanced cookstove intervention
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: IMCI pneumonia knowledge test
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Clinical evaluation checklist
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Key equipment checklist
Number of subjects: 176
Study: 25714132

Group type: EXPERIMENTAL
Intervention: Lower systolic BP
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Lower diastolic BP
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Lower mean arterial pressure (MAP)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Cortical gray matter or white matter volume
Number of subjects: 220
Study: 23477657

Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 2539

Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 2539
Study: 21169038

Group type: EXPERIMENTAL
Intervention: Resilon/Epiphany
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Resilon/Epiphany SE
Number of subjects: 36

Group type: COMPARATOR
Intervention: gutta‐percha/AH Plus
Number of subjects: 36
Study: 18604331

Group type: EXPERIMENTAL
Intervention: Celecoxib (accumulated dose of 400 mg)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Meloxicam (accumulated dose of 15 mg)
Number of subjects: 38
Study: 16311277

Group type: EXPERIMENTAL
Intervention: Magnesium 40 mg kg(‐1) bolus followed by magnesium 10 mg kg(‐1) h(‐1) infusion
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Magnesium 40 mg kg(‐1) bolus followed by magnesium 20 mg kg(‐1) h(‐1) infusion
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (normal saline)
Number of subjects: 80
Study: 12848834

Group type: EXPERIMENTAL
Intervention: LHWO+ME (Lay Health Worker Outreach + Media Education)
Number of subjects: 400

Group type: COMPARATOR
Intervention: ME (Media Education)
Number of subjects: 400
Study: 10910846

Group type: EXPERIMENTAL
Intervention: 0.02 mg/kg nicardipine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg diltiazem
Number of subjects: 45

Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 45
Study: 8721266

Group type: EXPERIMENTAL
Intervention: Radiation field size: 5 x 5 cm (Group A)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Radiation field size: 6 x 6 cm (Group B)
Number of subjects: 273
Study: 1411867

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3940258

Group type: EXPERIMENTAL
Intervention: Loperamide
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lidamidine 12 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lidamidine 18 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31314598

Group type: EXPERIMENTAL
Intervention: Lens 1 (radial refractive gradient design, nominal add power 2.00D)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lens 2 (center-near design, nominal add power 1.50D)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lens 3 (center-near design, nominal add power 2.00D)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Monofocal control lens
Number of subjects: 30
Study: 30355119

Group type: EXPERIMENTAL
Intervention: Extracranial ICA patent at day 1
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Successful recanalization (modified Thrombolysis in Cerebral Infarction, 2b/3)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Prior intravenous thrombolysis
Number of subjects: 83

Group type: COMPARATOR
Intervention: Cervical revascularization procedure (balloon angioplasty or stenting)
Number of subjects: 83
Study: 27253458

Group type: EXPERIMENTAL
Intervention: 5-week educational course and reinforcements every 4 months for one year
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control group (no structured diabetes mellitus education)
Number of subjects: 137
Study: 24555502

Group type: EXPERIMENTAL
Intervention: Home visiting nurse intervention (HVN)
Number of subjects: 499

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 499
Study: 22219343

Group type: EXPERIMENTAL
Intervention: I.V. acetazolamide (ACZ) 10 mg kg⁻¹
Number of subjects: 12
Study: 19424889

Group type: EXPERIMENTAL
Intervention: Telehealth intervention (Camperdown Program)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Face-to-face intervention (Camperdown Program)
Number of subjects: 40
Study: 18383657

Group type: EXPERIMENTAL
Intervention: Sucking ice during chemotherapy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Other treatments (not specified)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Analgesics (especially morphine)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Local anaesthetics
Number of subjects: 200
Study: 15928258

Group type: EXPERIMENTAL
Intervention: Black coffee
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Coffee with nondairy creamer and sugar
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no coffee)
Number of subjects: 40
Study: 12753443

Group type: EXPERIMENTAL
Intervention: Caudal block with bupivacaine 0.22% 4 mg.kg‐1 (1.8 ml.kg‐1) and morphine 150 microg x kg‐1
Number of subjects: 30

Group type: COMPARATOR
Intervention: General anaesthesia with fentanyl 25 microg x kg‐1
Number of subjects: 30

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Caudal block
Number of subjects: 30
Study: 10325255

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (stopped at menses) in IVF-SL group
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (continued throughout stimulation) in IVF-LL group
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (continued throughout stimulation) in oocyte donors
Number of subjects: 99
Study: 8565196

Group type: EXPERIMENTAL
Intervention: MethaSite (0.1% fluorometholone gel‐forming suspension)
Number of subjects: 105

Group type: COMPARATOR
Intervention: FML S.O.P. (0.1% fluorometholone ointment)
Number of subjects: 105
Study: 2016630

Group type: EXPERIMENTAL
Intervention: Prophylactic vancomycin 15 mg/kg every 12 hours from day -2 until resolution of neutropenia or until the first episode of fever
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no vancomycin)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Prophylactic vancomycin
Number of subjects: 60
Study: 7224109

Group type: EXPERIMENTAL
Intervention: 1 microgram terbutaline injected intradermally (i.d.)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 1 microgram terbutaline injected i.d. followed by allergen challenge
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Rechallenge with the same allergen or a dissimilar challenging agent
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Skin challenged with allergen in the presence of terbutaline
Number of subjects: 15

Group type: COMPARATOR
Intervention: Rechallenge with an unrelated allergen or compound 48/80
Number of subjects: 15
Study: 31067545

Group type: EXPERIMENTAL
Intervention: Mesalazine (4 g/day)
Number of subjects: 4
Study: 28687413

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg three times per week for 48 weeks
Number of subjects: 420

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420
Study: 25502348

Group type: EXPERIMENTAL
Intervention: Visual Illusion (VI)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Number of subjects: 24
Study: 23866815

Group type: EXPERIMENTAL
Intervention: Ongoing theory-based educational intervention with dedicated liaison practitioners to train clinical staff
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postal information about the local early intervention in psychosis service
Number of subjects: 0
Study: 20922542

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 40
Study: 19507456

Group type: EXPERIMENTAL
Intervention: e/Tablet electronic format
Number of subjects: 56

Group type: COMPARATOR
Intervention: paper version
Number of subjects: 56
Study: 16550416

Group type: EXPERIMENTAL
Intervention: Psychiatric day‐hospital treatment
Number of subjects: 202

Group type: COMPARATOR
Intervention: Inpatient treatment
Number of subjects: 202
Study: 15191512

Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolization (TACE)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Percutaneous acetic acid injection (PAI)
Number of subjects: 310
Study: 11135727

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 173

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 173
Study: 9820992

Group type: EXPERIMENTAL
Intervention: Simvastatin treatment to lower serum cholesterol
Number of subjects: 4444

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4444
Study: 7924771

Group type: EXPERIMENTAL
Intervention: Diabetic patients with diastolic dysfunction
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Diabetic patients with systolic dysfunction
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Diabetic patients with both diastolic and systolic dysfunction
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Diabetic patients with preserved diastolic function
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Diabetic patients with mild complications (DCI = 2)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Diabetic patients with more severe complications (DCI = 4)
Number of subjects: 157
Study: 2572495

Group type: EXPERIMENTAL
Intervention: Sulfasalazine prophylaxis (3 g daily for at least 2 years)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Nonradical operation
Number of subjects: 232

Group type: COMPARATOR
Intervention: Radical operation and placebo
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Nonradical operation and sulfasalazine
Number of subjects: 232
Study: 336304

Group type: EXPERIMENTAL
Intervention: 1.05 mg atropine
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 5.0 mg terbutaline
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 31446844

Group type: EXPERIMENTAL
Intervention: PBS + PLUS intervention delivered over 12 months by a transdisciplinary team including neuropsychologists, occupational therapists, and psychiatrists.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PBS + PLUS intervention
Number of subjects: 0
Study: 31754238

Group type: EXPERIMENTAL
Intervention: 8-month daily after-school aerobic exercise program (40 min/day, n=90)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Sedentary control condition (n=85)
Number of subjects: 175
Study: 31718297

Group type: EXPERIMENTAL
Intervention: Invasive strategy in addition to optimal medical therapy
Number of subjects: 3984
Study: 28103899

Group type: EXPERIMENTAL
Intervention: Intraoperative CT (CT group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Non-CT group (historical control)
Number of subjects: 50
Study: 25457792

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 900
Study: 23724771

Group type: EXPERIMENTAL
Intervention: Directed exercise focusing on hip and ankle strength and flexibility, completed over 10 sessions in a 2- to 3-week period.
Number of subjects: 32
Study: 22067885

Group type: EXPERIMENTAL
Intervention: 20mm short leg simulation
Number of subjects: 28

Group type: COMPARATOR
Intervention: NLLD (no leg length discrepancy)
Number of subjects: 28
Study: 19765846

Group type: EXPERIMENTAL
Intervention: VMAT2x
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: VMAT1x
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: MIMiC/IMRT(MLC)
Number of subjects: 9

Group type: COMPARATOR
Intervention: 3D‐CRT
Number of subjects: 9
Study: 17003303

Group type: EXPERIMENTAL
Intervention: Intensive multifactorial pharmacological treatment
Number of subjects: 196

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 196
Study: 12770610

Group type: EXPERIMENTAL
Intervention: AIT-082 100 mg/day
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: AIT-082 500 mg/day
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: AIT-082 2000 mg/day
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: AIT-082 (all doses)
Number of subjects: 36
Study: 10932569

Group type: EXPERIMENTAL
Intervention: Monroe's five-step sequence
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Reversed five steps
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Randomly ordered steps
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (unrelated message)
Number of subjects: 90
Study: 9298381

Group type: EXPERIMENTAL
Intervention: Postoperative intravenous drip infusion for 12-24 hours
Number of subjects: 60

Group type: COMPARATOR
Intervention: No postoperative intravenous drip infusion
Number of subjects: 60
Study: 8362425

Group type: EXPERIMENTAL
Intervention: Single-photon emission-computed tomography (SPECT)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Threshold value for SPECT graded scale
Number of subjects: 15
Study: 3793337

Group type: EXPERIMENTAL
Intervention: Caffeine ingestion (CW)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Caffeine ingestion (CC)
Number of subjects: 6
Study: 30025392

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 624

Group type: COMPARATOR
Intervention: Placebo (nonmetformin users)
Number of subjects: 624
Study: 27117440

Group type: EXPERIMENTAL
Intervention: Testosterone solution 2% (T-sol)
Number of subjects: 558
Study: 24642148

Group type: EXPERIMENTAL
Intervention: tamsulosin (0.4mg, three doses: 14 and 2 hours before, and 10 hours after surgery)
Number of subjects: 232

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 232
Study: 22181338

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (GBE) 120 mg/day for one month (n=10)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (n=13)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (GBE)
Number of subjects: 23
Study: 20042477

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 80
Study: 17947726

Group type: EXPERIMENTAL
Intervention: Capecitabine (1,000 mg/m2 twice daily for 2 weeks, followed by a 1-week break) + Erlotinib (150 mg daily)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Capecitabine + Erlotinib
Number of subjects: 30
Study: 15678055

Group type: EXPERIMENTAL
Intervention: TP‐10 (10 mg/kg)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 12841536

Group type: EXPERIMENTAL
Intervention: Methimazole (MMI) therapy, 10-30 mg for the first month and 5-10 mg from the second to the twelfth month.
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control group (Group 2) with normal serum TSH at the end of the first month of MMI therapy.
Number of subjects: 134
Study: 10812235

Group type: EXPERIMENTAL
Intervention: Live attenuated VZV vaccine (4000 PFU)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Inactivated VZV vaccine (equal volume to live vaccine)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 167
Study: 9678125

Group type: EXPERIMENTAL
Intervention: Oral contraceptives started on the first day of menses (day 1 group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oral contraceptives started on the fifth day after the onset of menses (day 5 group)
Number of subjects: 100